Curriculum

Reframing Acute Pain Management Through Opioid-Sparing Strategies and Novel Therapy

This three-part curriculum equips primary care clinicians to manage acute pain more effectively while reducing reliance on opioids. Through a text-based Expert Q&A, a case-based Clinical Coffee Break, and the adaptive AdaptED teaching module, learners will examine the consequences of undertreated acute pain, apply guideline-concordant, opioid-sparing strategies, and review the role of voltage-gated sodium channels in pain signaling. They will also summarize the clinical trial evidence for the selective NaV1.8 inhibitor suzetrigine and consider how to integrate this novel nonopioid option into acute pain treatment plans.

man grabbing shoulder in hospital gown

CME Information

2.00 AMA PRA Category 1 Credits™, 2.00 ABIM MOC or 2.08 AANP, 1.91 AANP Pharm

Release Date: 11/16/2026

Available for credit until 11/16/2027

Learning Objectives

  • Explain the consequences of inadequately treated acute pain, including delayed recovery, prolonged opioid use, and the transition from acute to chronic pain
  • Implement guideline-concordant, opioid-sparing strategies for acute pain management while minimizing risks associated with traditional nonopioid analgesics
  • Describe the role of voltage-gated sodium channels (VGSCs) in pain signal transmission and how selective inhibition of these channels can modulate acute pain pathways without addictive potential
  • Summarize the clinical trial evidence and appropriate use of the selective NaV1.8 inhibitor, suzetrigine, including how integrating this novel nonopioid therapy into acute pain treatment plans can reduce reliance on opioids

Courses

2.00 CME/CE CREDITS

3 Courses

Faculty

Steven Stanos, DO, FAAPMR

Clinical Instructor, UW Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, WA

Amy Clouse, MD, FAAFP

Clinical Associate Professor of Family and Community Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania

Supported By

Vertex Pharmaceuticals Incorporated

Education Partner

Pri-Med Institute